Patented cancer vaccines: the promising leads

Bibliography

• Available from: http://www.researchandmarkets.com/research/2a2448/launching_next_gen
   Google Scholar
• Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics 2009;12(5-6):319-30
   PubMedGoogle Scholar
• Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci 2009;46(4):167-89
   PubMedGoogle Scholar
• Available from: http://www.MarketResearch.com
   Google Scholar
• Available from: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatory Information/Guidances/Vaccines/ucm182443.htm
   Google Scholar
• Available from: http://www.kaloramainformation.com/
   Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353(9150):345-50
   PubMedGoogle Scholar
• Berd D, Sato T, Maguire HC, Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22(3):403-15
   PubMedGoogle Scholar
• Jocham D, Richter A, Hoffmann L, Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-9
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008;57(10):1569-77
   PubMedGoogle Scholar
• Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006;25(5-6):321-52
   PubMedGoogle Scholar
• H Lee Moffitt Cancer Center and Research Institute Inc. Chemokine gene-modified cells for cancer immunotherapy. WO2009117566; 2009
   Google Scholar
• Kallen KJ, zum Buschenfelde KH, Rose-John S. The therapeutic potential of interleukin-6 hyperagonists and antagonists. Expert Opin Investig Drugs 1997;6(3):237-66
   PubMedGoogle Scholar
• AGIRx Limited, UK. Anticancer vaccine compositions comprising allogenic tumor cells modified with hyper-cytokines, particularly for the treatment of melanoma. WO2009095261; 2009
   Google Scholar
• Morphogenesis, Inc. Tumor cell vaccines. WO2009117011; 2009
   Google Scholar
• Bergman PJ, Camps-Palau MA, McKnight JA, Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24(21):4582-5
   PubMedGoogle Scholar
• Bergman PJ, McKnight J, Novosad A, Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9(4):1284-90
   PubMedGoogle Scholar
• Liao JC, Gregor P, Wolchok JD, Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006;6:8
   PubMedGoogle Scholar
• Peruzzi D, Mesiti G, Ciliberto G, Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010;28(5):1201-8
   Google Scholar
• Steer AC, Law I, Matatolu L, Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009;9(10):611-6
   PubMedGoogle Scholar
• Ribas A, Butterfield LH, Glaspy JA, Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21(12):2415-32
   PubMedGoogle Scholar
• University of Miami. Immunotherapy based on allogeneic cancer cells secreting a modified heat shock protein, such as gp96. WO2009114085; 2009
   Google Scholar
• Campi G, Crosti M, Consogno G, CD4+ T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 2003;63:8481-6
   PubMedGoogle Scholar
• Frenoy N, Schauffler J, Cahour A, Burtin P. Natural antibodies against the carcinoembryonic antigen (CEA) and a related antigen, NCA, in human sera. Anticancer Res 1987;7:1229-33
   PubMed Web of Science ®Google Scholar
• Fuchs C, Krapf F, Kern P, CEA-containing immune complexes in sera of patients with colorectal and breast cancer: analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 1988;26:180-4
   PubMed Web of Science ®Google Scholar
• Huarte E, Sarobe P, Lasarte JJ, Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembrynic antigen. Int J Cancer 2002;97:58-63
   PubMedGoogle Scholar
• Kawashima I, Hudson SJ, Tsai V, The multiepitope approach for immunotherapy for cancer: identification of several CTL epitopes from tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1-14
   PubMed Web of Science ®Google Scholar
• Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol 2003;30(3 Suppl 8):30-6
   PubMedGoogle Scholar
• Shumway NM, Ibrahim N, Ponniah S, Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009;23(5):277-87
   PubMedGoogle Scholar
• Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 2008;90(1):173-80
   PubMedGoogle Scholar
• Chaudry MA, Sales K, Ruf P, EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 2007;96(7):1013-9
   PubMedGoogle Scholar
• Andersen MH, thor SP. Survivin–a universal tumor antigen. Histol Histopathol 2002;17(2):669-75
   PubMedGoogle Scholar
• Doehn C, Bohmer T, Kausch I, Prostate cancer vaccines: current status and future potential. BioDrugs 2008;22(2):71-84
   PubMedGoogle Scholar
• Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006;5(5):707-16
   PubMedGoogle Scholar
• Cavallo F, Offringa R, van der Burg SH, Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006;90:175-213
   PubMedGoogle Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117(5):1195-203
   PubMed Web of Science ®Google Scholar
• McNeel DG, Dunphy EJ, Davies JG, Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009;27(25):4047-54
   PubMedGoogle Scholar
• Yuan J, Ku GY, Gallardo HF, Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009;9:5
   PubMedGoogle Scholar
• Carmichael MG, Benavides LC, Holmes JP, Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010;116(2):292-301
   PubMedGoogle Scholar
• Miyazawa M, Ohsawa R, Tsunoda T, Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010;101(2):433-39 (7)
   PubMedGoogle Scholar
• Rhovac ApS, Den. Rhoc-based immunotherapy. WO2009076966; 2009
   Google Scholar
• Clark EA, Golub TR, Lander ES, Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406(6795):532-5
   PubMedGoogle Scholar
• Kleer CG, van Golen KL, Zhang Y, Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002;160(2):579-84
   PubMedGoogle Scholar
• Horiuchi A, Imai T, Wang C, Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83(6):861-70
   PubMedGoogle Scholar
• Caprion Pharmaceutical Inc. Lung cancer-associated tumor antigen TAT-039, and methods of assessing and treating cancer. WO2007089659; 2007
   Google Scholar
• Agensys, Inc. Nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer. US7585505; 2009
   Google Scholar
• Kebache S, Ash J, Annis MG, Grb10 and active Raf-1 kinase promote Bad-dependent cell survival. J Biol Chem 2007;282(30):21873-83
   PubMedGoogle Scholar
• University of Illinois. Mammalian cell expressing tumor-associated antigen Grb10 or others as vaccine for cancer therapy. WO2009114816; 2009
   Google Scholar
• Sood A. Anti-PDEF (prostate-derived Ets factor) antibodies for diagnosing and treating cancer, as well as PDEF-comprising tumor vaccines. US20090202595; 2009
   Google Scholar
• Wei L, Shi YB. Matrix metalloproteinase stromelysin-3 in development and pathogenesis. Histol Histopathol 2005;20(1):177-85
   PubMedGoogle Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-74
   PubMed Web of Science ®Google Scholar
• Mari BP, Anderson IC, Mari SE, Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem 1998;273(1):618-26
   PubMedGoogle Scholar
• Peruzzi D, Mori F, Conforti A, MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res 2009;15(12):4104-13
   PubMedGoogle Scholar
• Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Matrix Metalloproteinase 11 Vaccine. WO2007042169; 2007
   Google Scholar
• Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 2004;1695(1-3):225-33
   PubMedGoogle Scholar
• Kapil M. DNA Vaccine for Cancer Therapy. US2009221682; 2009
   Google Scholar
• Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof WO2008043760; 2008
   Google Scholar
• Mennuni C, Ugel S, Mori F, Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008;68(23):9865-74
   PubMedGoogle Scholar
• Dharmapuri S, Peruzzi D, Mennuni C, Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther 2009;17:1804-13
   Google Scholar
• Jacobs JF, Aarntzen EH, Sibelt LA, Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 2009;58(1):145-51
   PubMedGoogle Scholar
• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247(4944):824-30
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7
   PubMed Web of Science ®Google Scholar
• Goddard AD, Borrow J, Freemont PS, Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991;254(5036):1371-4
   PubMedGoogle Scholar
• Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol 2009;16(3):145-53
   PubMedGoogle Scholar
• Arizona State University. Peptide variants associated with somatic mutation in cancer and their use in the diagnosis and immunotherapy of cancer WO2007101227; 2007
   Google Scholar
• Genitope Corporation. Vaccines comprising surface antigen epitope and surface antigen-specific monoclonal antibody for combination immunotherapy of B cell malignancy. WO2007067780; 2007
   Google Scholar
• University of California. Glycopeptides comprising tumor-associated carbohydrate antigen that direct against CTLs or helper T cells for immunotherapy of carcinomas. WO2009108807; 2009
   Google Scholar
• Franco A. Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions. Anticancer Agents Med Chem 2008;8(1):86-91
   PubMedGoogle Scholar
• Livingston PO, Ritter G, Srivastava P, Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49(24 Pt 1):7045-50
   PubMed Web of Science ®Google Scholar
• Memorial Sloan-Kettering Cancer. Glycoconjugates comprising carbohydrate epitopes, methods for their synthesis, and their use for the treatment or prophylaxis of cancer. WO2004011476; 2004
   Google Scholar
• University of Georgia Research Foundation, Inc. Glycolipopeptides and uses thereof in vaccines. US20090041836; 2009
   Google Scholar
• The Scripps Research Institute, USA. Antigen or self-antigen genetically encoded unnatural amino acid for breaking immune tolerance and treating cancer, infection or autoimmune disease. WO2009099672; 2009
   Google Scholar
• Sette A, Alexander J, Ruppert J, Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol 1994;12:413-31
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich NP, SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50(3-4):213-9
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. System and method for automated selection of T-cell epitopes. WO2006124408; 2006
   Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190(3):355-66
   PubMed Web of Science ®Google Scholar
• Ludewig B, Ochsenbein AF, Odermatt B, Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191(5):795-804
   PubMedGoogle Scholar
• Keogh E, Fikes J, Southwood S, Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001;167(2):787-96
   PubMedGoogle Scholar
• Epimmune, Inc. HLA binding motifs and immunogenic peptides and their uses for vaccines against desired antigens. US20070055049; 2007
   Google Scholar
• Henry M. Jackson Foundation for the Advancement of Military Medicine Institute. Targeted identification of immunogenic peptides. WO2009112792; 2009
   Google Scholar
• Aparna Biosciences, USA. Therapeutic and vaccine polyelectrolyte nanoparticle compositions. WO2009079066; 2009
   Google Scholar
• Alpha-O Peptides AG, Switz. Self-assembling peptide nanoparticles comprising T cell epitopes and/or B cell epitopes useful as vaccines. WO2009109428; 2009
   Google Scholar
• Wuest T, Both GW, Prince AM, Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004;22(21-22):2717-21
   PubMedGoogle Scholar
• McCoy K, Tatsis N, Korioth-Schmitz B, Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007;81(12):6594-604
   PubMed Web of Science ®Google Scholar
• Tatsis N, Tesema L, Robinson ER, Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006;13(5):421-9
   PubMed Web of Science ®Google Scholar
• Zhi Y, Figueredo J, Kobinger GP, Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 2006;17(5):500-6
   PubMedGoogle Scholar
• Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 2005;79(23):14595-605
   PubMedGoogle Scholar
• Perreau M, Mennechet F, Serratrice N, Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 2007;81(7):3272-84
   PubMedGoogle Scholar
• Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 2004;105(2):127-36
   PubMed Web of Science ®Google Scholar
• Peruzzi D, Dharmapuri S, Cirillo A, A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009;27(9):1293-300
   PubMed Web of Science ®Google Scholar
• Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Chimpanzee adenovirus vaccine carriers.WO2005071093; 2005
   Google Scholar
• The Trustees of the University of Pennsylvania, USA. Sequences for simian adenoviruses of subfamily C, SAdV-40, SAdV-31 or SAdV-34, and uses thereof for gene delivery, vaccination and recombinant production. WO2009105084; 2009
   Google Scholar
• Brockstedt DG, Dubensky TW. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Expert Rev Vaccines 2008;7(7):1069-84
   PubMedGoogle Scholar
• Paterson Y, Maciag P, Seavey M, Recombinant Listeria expressing High Molecular Weight Melanoma-Associated Antigen Protein (HMW-MAA) and fragments thereof, and methods of use thereof for cancer immunotherapy. US 20090202587; 2009
   Google Scholar
• Cerus Corporation, USA; Anza Therapeutics, Inc. Inactivated Listeria comprising plasmid vector encoding holin protein and tumor antigen or infectious agent antigen as vaccines against cancer and infection. WO2008027560; 2008
   Google Scholar
• GlobeImmune Inc. Yeast-based vaccine for inducing an immune response. WO2007092792; 2007
   Google Scholar
• GlobeImmune Inc. Ras mutations and compositions and methods related thereto. WO2007133835; 2007
   Google Scholar
• Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Peop. Rep. China Recombinant plasmodium for expressing exogenous gene of vaccine and antigen. CN101492643; 2009
   Google Scholar
• University of California. Immunostimulatory combinations of receptor agonists for vaccines and tumor immunotherapy. WO2007120368; 2007
   Google Scholar
• University of Pennsylvania. Methods and compositions for modulating T cell homing to solid tumors to enhance immunotherapy of tumor vaccines. US20090214518; 2009
   Google Scholar
• Masotti A, Ortaggi G. Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Rev Med Chem 2009;9(4):463-9
   PubMed Web of Science ®Google Scholar
• United States Dept. of Health and Human Services, US. Chitosan enhancement of immune responses. WO2008039390; 2008
   Google Scholar
• Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008;13(Suppl 4):2-9
   PubMedGoogle Scholar
• Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 2008;13(Suppl 4):10-5
   PubMedGoogle Scholar
• Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008;13(Suppl 4):16-25
   PubMedGoogle Scholar
• Medarex, Inc. Anti-CTLA-4 antibodies with no CTLA-4-B7 binding inhibition for inducing T cell response to antigenic stimulation and treating cancer. WO2009100140; 2009
   Google Scholar
• Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27(2):161-7
   PubMedGoogle Scholar
• Coley Pharmaceuticals GmbH. Immunostimulatory P-class oligonucleotide formulations for use in treating diseases and as vaccine adjuvants. WO2007095316; 2007
   Google Scholar
• van der Most RG, Currie A, Robinson BW, Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006;66(2):601-4
   PubMedGoogle Scholar
• Bracci L, Moschella F, Sestili P, Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007;13(2 Pt 1):644-53
   PubMedGoogle Scholar
• Ghiringhelli F, Menard C, Puig PE, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641-8
   PubMedGoogle Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4
   PubMed Web of Science ®Google Scholar